Current Clinical Practice and NCCN Guidelines for CLL/SLL

CCO Oncology Podcast

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2M ago 31:33

MP3•Episode home

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

Prognostic variables when deciding between regimens
Role of MRD in CLL
Results from the phase II CAPTIVATE trial
Choosing among the available covalent BTK inhibitors
Preferred partner anti-CD20 antibody in CLL/SLL
Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

181 episodes

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #Essential Thrombocythemia #Myelofibrosis #Oncology #CME #Nonmalignant Hematological Disorders #Skin Cancer #Hematological Malignancies #Acute Myeloid Leukemia #Kidney Cancer #Melanoma #Gastrointestinal Cancer #Acute Lymphocytic Leukemia #Prostate Cancer #Myeloproliferative Neoplasms #Follicular Lymphoma #Glioblastoma #Nsclc #Multiple Myeloma #Hodgkin Lymphoma #Basal Cell Carcinoma #All #Polycythemia Vera #Breast Cancer #Dlbcl #Head And Neck Cancer #Liver Cancer #Sarcoma #Gastroesophageal Cancer #Lung Cancer #Hepatocellular Carcinoma #Urothelial Carcinoma #Cancer Screening #Renal Cell Carcinoma #AML #Ovarian Cancer #CPE #Lymphoma #Diffuse Large B-cell Lymphoma #Cll #Pancreatic Cancer #Beta-thalassemia #Chronic Myeloid Leukemia